Pharma News

Samumed’s Experimental Drug Initial Results Show Effective Bald Treatment

Samumed’s Experimental Drug Initial Results Show Effective Bald Treatment

A presentation to the American Academy of Dermatology in Washington, D.C. has shown that an experimental drug from Samumed, an unknown San-Diego-based biotechnology firm, is efficient in growing hair among bald men. The preliminary data, delivered by Yusuf Yazici, Samumed Chief Medical Officer, have demonstrated ‘promising’ results. However, there are many concerns whether the drug will hold up in larger[Read More…]

by October 18, 2016
Biotech Stocks Update: Celgene Corporation (NASDAQ:CELG), Pfizer, Inc. (NYSE:PFE), WebMD Health Corporation (NASDAQ:WBMD)

Biotech Stocks Update: Celgene Corporation (NASDAQ:CELG), Pfizer, Inc. (NYSE:PFE), WebMD Health Corporation (NASDAQ:WBMD)

Celgene Corporation (NASDAQ:CELG) Celgene predicts a whopping $21 billion sales by 2020, marking over 100% increase from its sales today. Currently, the company has a total amount of $7.50 billion cash on hand. Celgene holds a ‘cheap’ forward price to earnings (P/E) ratio of 13.85. Investors remain optimistic about the healthcare company’s upbeat projections. Moreover, a great cash-on-hand also indicates[Read More…]

by September 16, 2016
Dividend News: Otter Tail Corporation (NASDAQ:OTTR), BIO-TECHNE Corp (NASDAQ:TECH) and Eli Lilly and Co (NYSE:LLY)

Dividend News: Otter Tail Corporation (NASDAQ:OTTR), BIO-TECHNE Corp (NASDAQ:TECH) and Eli Lilly and Co (NYSE:LLY)

Otter Tail Corporation (NASDAQ:OTTR) to distribute $0.3125 per share in dividends in March: Otter Tail Corporation (NASDAQ:OTTR) intends to pay a quarterly dividend of $0.3125 per share on March 10, 2016. The dividend will captured investors who get into the stock before Feb. 10, 2016. As a percentage of the recent stock price, Otter’s quarterly dividend represents 1.10% yield. Otter[Read More…]

by August 23, 2016
Clinical Trials Confirms That Regeneron Pharmaceuticals Inc (NASDAQ:REGN)’s Eylea Is Better Compared To Genentech’s Avastin

Clinical Trials Confirms That Regeneron Pharmaceuticals Inc (NASDAQ:REGN)’s Eylea Is Better Compared To Genentech’s Avastin

Clinical trials of three drugs have given Regeneron Pharmaceuticals Inc (NASDAQ:REGN)’s Eylea an upper hand in the treatment diabetic macular edema (DME) against Genentech’s Avastin and Lucentis. However, all the three have commendable effectiveness but Eylea is a notch higher in managing DME patients with moderate visual acuity of 20/50 or worse. The rigorous trial which enrolled 660 people with[Read More…]

by February 29, 2016